Valeant goes in search of a remedy with loans in danger of covenant breach
Painkillers won't do - large loan issuer Valeant Pharmaceuticals is going to need something stronger as it looks to stave off a possible default
Subscriber-only article
This article is available only to Creditflux subscribers and free trial users within 30 days of publication.
Already a subscriber? Not logged in? Click here to login.
If you have not already done so,
you may request a FREE TRIAL by clicking here
This trial will give you:
- 4-weeks' free online access to our
most recent subscriber-only articles - Daily breaking news alert sent by email
- A print copy of Creditflux
If you currently have a free trial, you will see this message when you try to view articles older than 30 days.
Related Stories
- Distress rises in US CLO double Bs — but most have been in trouble for years 5 days ago
- Altice isn’t just a European CLO problem 28 days ago
- Global corporate defaults on fastest pace since 2009 according to S&P 1 month ago
- Troubled European name reaches end-game 2 months ago
- Electronic controls company Robertshaw is latest CLO name to default 2 months ago
CLOs
- Third time's the charm as 2013 vintage CLO gets reset 6 hours ago
- European reset highlights weakness in mezz despite robust senior demand 1 day ago
- Elmwood prints eighth deal this year 1 day ago
- Partnership with Jefferies bears fruit as manager returns to CLO primary 2 days ago
- US resets continue as Redding Ridge joins in 2 days ago
Comment by: Anonymous. Posted 8 years ago [2016-03-16 23:46:27]